NFE2L2 and metabolic dysfunction-associated steatohepatitis: More recently, the same group of authors (Sharma et al., 2017) demonstrated that a potent pharmacologic activator of Nrf2 (TBE-31) ameliorated experimental NASH and liver fibrosis reducing insulin resistance, suppressing hepatic steatosis, and inhibiting inflammatory response and oxidative stress.